Understanding the neurocognitive heterogeneity in bipolar disorder
了解双相情感障碍的神经认知异质性
基本信息
- 批准号:9493978
- 负责人:
- 金额:$ 44.38万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2017
- 资助国家:美国
- 起止时间:2017-08-01 至 2019-04-30
- 项目状态:已结题
- 来源:
- 关键词:Activities of Daily LivingAcuteAddressAffectiveAffective SymptomsAlcohol or Other Drugs useAnxiety DisordersArchitectureAreaAttentionBiologicalBiological AssayBiological MarkersBipolar DisorderBlood specimenBrain-Derived Neurotrophic FactorCategoriesChild AbuseCircadian RhythmsClinicalClinical MarkersCluster AnalysisCognitiveCommunitiesComorbidityDataData AnalyticsDevelopmental CourseDiagnosticDimensionsDiseaseDisease remissionEtiologyEvaluationFrequenciesFutureHeterogeneityImpaired cognitionImpairmentIndependent LivingIndividualInterleukin-12Interleukin-2MeasuresMediator of activation proteinMedicalModelingNeurocognitionNeurocognitiveNeurocognitive DeficitNeuropsychologyOccupationalOutcomePatientsPatternPeripheralPhenotypePsychotic DisordersQuality of lifeRecording of previous eventsRecoveryResearchRiskRoleSamplingSchizophreniaSeveritiesSleepStructureSubgroupTNF geneTestingVerbal Learningabuse neglectbasecognitive performancecohortcytokinedesigndisabling symptomeffective therapyexecutive functionfunctional disabilityfunctional outcomesinflammatory markerinsightneurotrophic factornovelnovel strategiespediatric traumaperformance testspublic health relevancesocialtrait
项目摘要
DESCRIPTION (provided by applicant): Patients with bipolar disorder (BPD) were once thought to achieve complete inter-episode recovery, particularly with regard to cognitive dysfunction. More recent data suggest a persistent, trait-like pattern of neurocognitive impairments in BPD, even during periods of affective remission. At the group level, the severity of these deficits is 3/4 to 1 full standard deviation below average, which is significantly less severe than deficits noted in schizophrenia (SZ). Recent evidence, however, suggests that the frequency of cognitive impairment in euthymic BPD patients is ~40-60%, with a substantial proportion of patients characterized as cognitively- spared. This contrasts with the relative homogeneity of this phenotype in SZ where > 90% of patients demonstrates significant impairment. A better understanding of the cognitive heterogeneity in BPD, why some patients develop significant cognitive difficulties while others do not, is critical toward optimizing patiets' quality of life. The current proposal aims to determine the clinical and biological predictors of cognitive impairment in 350 patients with BPD using a novel approach. We will empirically test for homogeneous subgroups within the sample based neurocognitive performance and test a cassette of clinical features and biomarkers as potential predictors of impairment. We will also investigate the relationship between neurocognitive functioning and everyday functional capacity in the areas of occupational, social and independent living ability. Data will provide important information on the underlying structure of neurocognition in BPD and its etiology, guiding future efforts to target these disabling symptoms with treatment.
描述(由申请人提供):双相情感障碍(BPD)患者曾经被认为能够在发作间期完全恢复,特别是在认知功能障碍方面。最近的数据表明,即使在情感缓解期间,BPD 也存在持续的、类似特征的神经认知损伤模式。在群体水平上,这些缺陷的严重程度比平均水平低 3/4 到 1 个完整标准差,明显低于精神分裂症 (SZ) 中注意到的缺陷严重程度。然而,最近的证据表明,情绪正常的 BPD 患者出现认知障碍的频率约为 40-60%,其中相当大比例的患者具有认知障碍。这与 SZ 中该表型的相对同质性形成鲜明对比,其中 > 90% 的患者表现出显着的损伤。更好地理解边缘性人格障碍的认知异质性,以及为什么一些患者会出现明显的认知困难而另一些患者则不会的原因,对于优化患者的生活质量至关重要。目前的提案旨在使用一种新方法确定 350 名 BPD 患者认知障碍的临床和生物学预测因子。我们将根据经验测试样本中基于神经认知表现的同质亚组,并测试一系列临床特征和生物标志物作为潜在的损伤预测因子。我们还将研究神经认知功能与职业、社交和独立生活能力领域日常功能能力之间的关系。数据将提供有关 BPD 神经认知的基本结构及其病因学的重要信息,指导未来针对这些致残症状的治疗。
项目成果
期刊论文数量(3)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
TNF-α and its soluble receptors mediate the relationship between prior severe mood episodes and cognitive dysfunction in euthymic bipolar disorder.
TNF-α 及其可溶性受体介导正常双相情感障碍中先前严重情绪发作和认知功能障碍之间的关系。
- DOI:
- 发表时间:2020
- 期刊:
- 影响因子:0
- 作者:Millett, C E;Harder, J;Locascio, J J;Shanahan, M;Santone, G;Fichorova, R N;Corrigan, A;Baecher;Burdick, K E
- 通讯作者:Burdick, K E
C-reactive protein is associated with cognitive performance in a large cohort of euthymic patients with bipolar disorder.
C反应蛋白与一大群心境正常的双相情感障碍患者的认知表现相关。
- DOI:
- 发表时间:2021-08
- 期刊:
- 影响因子:11
- 作者:Millett, C E;Perez;Shanahan, M;Larsen, E;Yamamoto, H S;Bukowski, C;Fichorova, R;Burdick, K E
- 通讯作者:Burdick, K E
Patterns of pharmacotherapy for bipolar disorder: A GBC survey.
双相情感障碍的药物治疗模式:GBC 调查。
- DOI:
- 发表时间:2024-02
- 期刊:
- 影响因子:5.4
- 作者:Singh, Balwinder;Yocum, Anastasia K;Strawbridge, Rebecca;Burdick, Katherine E;Millett, Caitlin E;Peters, Amy T;Sperry, Sarah H;Fico, Giovanna;Vieta, Eduard;Verdolini, Norma;Godin, Ophelia;Leboyer, Marion;Etain, Bruno;Tso, Ivy F;Coombes, Bran
- 通讯作者:Coombes, Bran
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Katherine Elizabeth Burdick其他文献
Katherine Elizabeth Burdick的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Katherine Elizabeth Burdick', 18)}}的其他基金
Using allopregnanolone to probe behavioral and neurobiological mechanisms that underlie depression in women across perimenopausal stage
使用四氢孕酮探讨围绝经期女性抑郁症的行为和神经生物学机制
- 批准号:
10358658 - 财政年份:2022
- 资助金额:
$ 44.38万 - 项目类别:
Using allopregnanolone to probe behavioral and neurobiological mechanisms that underlie depression in women across perimenopausal stage
使用四氢孕酮探讨围绝经期女性抑郁症的行为和神经生物学机制
- 批准号:
10557128 - 财政年份:2022
- 资助金额:
$ 44.38万 - 项目类别:
Brain-based Mechanisms of Emotion Regulation in Aging and Mood Disorders
衰老和情绪障碍中基于大脑的情绪调节机制
- 批准号:
10154000 - 财政年份:2020
- 资助金额:
$ 44.38万 - 项目类别:
Brain-based Mechanisms of Emotion Regulation in Aging and Mood Disorders
衰老和情绪障碍中基于大脑的情绪调节机制
- 批准号:
10514586 - 财政年份:2020
- 资助金额:
$ 44.38万 - 项目类别:
Brain-based Mechanisms of Emotion Regulation in Aging and Mood Disorders
衰老和情绪障碍中基于大脑的情绪调节机制
- 批准号:
10319173 - 财政年份:2020
- 资助金额:
$ 44.38万 - 项目类别:
1/2-Pramipexole in Bipolar Disorder: Targeting Cognition (PRAM-BD)
1/2-普拉克索治疗双相情感障碍:目标认知 (PRAM-BD)
- 批准号:
9070766 - 财政年份:2014
- 资助金额:
$ 44.38万 - 项目类别:
Neurocognitive Heterogeneity in Patients with Psychosis _ A Dimensional Approach
精神病患者的神经认知异质性_维度方法
- 批准号:
8828502 - 财政年份:2014
- 资助金额:
$ 44.38万 - 项目类别:
Neurocognitive Heterogeneity in Patients with Psychosis _ A Dimensional Approach
精神病患者的神经认知异质性_维度方法
- 批准号:
8634973 - 财政年份:2014
- 资助金额:
$ 44.38万 - 项目类别:
1/2-Pramipexole in Bipolar Disorder: Targeting Cognition (PRAM-BD)
1/2-普拉克索治疗双相情感障碍:目标认知 (PRAM-BD)
- 批准号:
8760643 - 财政年份:2014
- 资助金额:
$ 44.38万 - 项目类别:
Targeting Circadian and Cognitive Dysfunction in Bipolar Disorder with Modafinil
用莫达非尼治疗双相情感障碍的昼夜节律和认知功能障碍
- 批准号:
8566925 - 财政年份:2013
- 资助金额:
$ 44.38万 - 项目类别:
相似国自然基金
巨噬细胞Nogo-B通过FABP4/IL-18/IL-18R调控急性肝衰竭的分子机制研究
- 批准号:82304503
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
α7nAChR激动剂通过PGC-1α和HO-1调控肾小管上皮细胞线粒体的质和量进而改善脓毒症急性肾损伤的机制研究
- 批准号:82372172
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
基于解郁散热“把好气分关”探讨代谢-炎症“开关”A2BR在急性胰腺炎既病防变中的作用与机制
- 批准号:82374256
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
RacGAP1介导细胞核-线粒体对话在急性肾损伤中促进肾小管上皮细胞能量平衡的作用机制研究
- 批准号:82300771
- 批准年份:2023
- 资助金额:30 万元
- 项目类别:青年科学基金项目
开窍寒温配伍调控应激颗粒铁离子富集水平抗急性缺血性卒中铁死亡损伤的机制研究
- 批准号:82374209
- 批准年份:2023
- 资助金额:49 万元
- 项目类别:面上项目
相似海外基金
Next Generation Opto-GPCRs for Neuromodulatory Control
用于神经调节控制的下一代 Opto-GPCR
- 批准号:
10515612 - 财政年份:2023
- 资助金额:
$ 44.38万 - 项目类别:
Development and Validation of the Down Syndrome Regression Rating Scales
唐氏综合症回归评定量表的开发和验证
- 批准号:
10781052 - 财政年份:2023
- 资助金额:
$ 44.38万 - 项目类别:
Pterygopalatine Fossa (PPF) Block as an Opioid Sparing Treatment for AcuteHeadache in Aneurysmal Subarachnold Hemorrhage
翼腭窝 (PPF) 阻滞作为阿片类药物节省治疗动脉瘤性蛛网膜下腔出血的急性头痛
- 批准号:
10584712 - 财政年份:2023
- 资助金额:
$ 44.38万 - 项目类别:
Racial Differences in Hospital-Associated Disability and Acute and Post-Acute Care Physical Therapy Utilization
医院相关残疾以及急性和急性后护理物理治疗利用的种族差异
- 批准号:
10785500 - 财政年份:2023
- 资助金额:
$ 44.38万 - 项目类别:
The Protective and Pathologic Features of the EVD Survivor Immune System
埃博拉病毒病幸存者免疫系统的保护和病理特征
- 批准号:
10639583 - 财政年份:2023
- 资助金额:
$ 44.38万 - 项目类别: